Corticosteroids such as methylprednisolone (MP) remain the primary therapy for acute GVHD (aGVHD). Patients who are refractory to standard treatment (MP 2 mg/kg/day) may be treated with high-dose MP. This study evaluated the response to high-dose MP in children with aGVHD refractory to standard dose MP. Children who underwent hematopoietic SCT (HSCT) at our hospital between 1 June 2002 and 31 July 2006 and were treated with high-dose MP upon developing steroid-refractory aGVHD were included. Response to aGVHD therapy, adverse effects attributed to MP and overall outcomes were documented. Ten children received high-dose MP (X20 mg/kg/day) on 3-5 consecutive days followed by a tapering dose for steroid-refractory aGVHD, at a median of 12 days after starting standard treatment. Nine patients had Xgrade III aGVHD. Only one patient with grade III aGVHD had a complete response. Two patients had a partial response but flared when MP was tapered. Complications included hypertension (100%), hyperglycemia requiring insulin therapy (33%) and four documented severe infections. Five children (50%) died (median follow-up: 5.9 years). Salvage therapy other than high-dose MP should be considered in children who fail to respond to MP 2 mg/kg/day.
Introduction
Despite prophylaxis, acute GVHD (aGVHD) remains a major cause of morbidity and mortality in patients undergoing allogeneic hematopoietic SCT (HSCT). 1, 2 The reported incidence of aGVHD ranges from 30 to 80%. 3 The most common aGVHD prophylaxis regimen is a combination of calcineurin inhibitors (CYA or tacrolimus) and short-course MTX. When aGVHD arises, most centers continue immunosuppression with calcineurin inhibitors and add a corticosteroid such as methylprednisolone (MP) at a standard dose of 2 mg/kg/day for 14 days and then taper the dose. 3 Sustained complete response rates to standard corticosteroid doses are reported to range from as high as 70% to as low as 35%. 3, 4 Patients who do not respond to corticosteroid treatment are considered to have corticosteroid-resistant disease. The choice of salvage therapy is not clear and corticosteroidresistant aGVHD is associated with high treatment-related mortality. 5, 6 The use of polyclonal anti-thymocyte globulin, monoclonal antibodies (such as daclizumab and infliximab), mycophenolate mofetil, high-dose corticosteroids and others has been reported. 3 As no single approach to therapy is generally acknowledged to be superior, there is a wide variation in the treatment of corticosteroid-resistant aGVHD among transplant centers. Historically, our center has treated patients with aGVHD and overlap syndrome that are non-responsive to standard corticosteroid doses with higher corticosteroid doses. The aim of this study is to evaluate the response to high-dose corticosteroid in children with standard dose corticosteroid-resistant GVHD.
Patients and methods
The study was approved by the research ethics board of our hospital.
Patients
Before 1 August 2006 it was our institutional practice to treat aGVHD in patients who failed to respond to IV MP 2 mg/kg/day with an increased MP dose. In this review, we included all children aged 18 years or less who underwent HSCT for indications other than severe combined immunodeficiency between 1 June 2002 to 31 July 2006 at our institution and developed aGVHD of grade II or higher.
Patients who had not received corticosteroid as prophylaxis for aGVHD, who developed aGVHD of grade II or higher, who had received 2 mg/kg/day MP IV divided q12h as initial therapy for aGVHD but did not respond to this therapy and who received high-dose MP (20 mg/kg/day or more) for at least 3 days were included. Corticosteroid therapy was tapered at the discretion of the treating team; the tapering schedule was not standardized.
Supportive care
All patients received aGVHD prophylaxis initially with MTX and either CYA or tacrolimus. Our MTX dosing regimen changed during the study period. Patients received four doses of MTX 10 mg/m 2 either on days þ 3, þ 6, þ 11, þ 18 or on days þ 1, þ 3, þ 6, þ 11. The method used to determine whole blood CYA concentrations changed over the study time period. Data were collected from the patient's health record and/ or pharmacy record including demographic information; primary diagnosis; HSCT date; conditioning regimen; aGVHD prophylactic regimen; assessment and grading of aGVHD or overlap syndrome and organ(s) involved; aGVHD treatment regimens, and time interval between the diagnosis of aGvHD and the initiation of standard dose corticosteroid and high-dose corticosteroid treatment. Patients were followed until death or their last hospital visit.
Response assessment aGVHD was graded according to the classic GlucksbergSeattle system. 7, 8 Overlap syndrome was defined as combined features of both acute and chronic GVHD. Corticosteroid-resistant aGVHD was defined as failure to respond to treatment with MP 2 mg/kg/day after a minimum of 5 days of therapy, progression of symptoms after a minimum of 3 days of MP treatment or a flare of symptoms when MP was weaned. 10 Treatment response criteria (CR and PR) were defined as per Przepiorka and Martin. 11, 12 That is, CR was defined as resolution of all signs and symptoms of aGVHD and PR was defined as a reduction of at least one stage in at least one organ, without worsening in other organ systems. Day 28 was chosen as the timing of end point measurement as recently recommended by Martin et al. 12 As this was a retrospective chart review, response was evaluated by two physician authors (TS, JD). If the assessments of these physicians differed, a final decision was made by consensus.
Morbidity and mortality
Details regarding the occurrence of infection, hypertension and hyperglycemia requiring insulin therapy were recorded. Clinical or microbiologically confirmed infections were identified. In addition, any adverse effect attributed to corticosteroid treatment by the treatment team and recorded in the health record was noted. All adverse events, including relapse and death, which occurred subsequent to the initiation of high-dose corticosteroid administration, were recorded.
Results
Fifty children were diagnosed with aGVHD and treated with standard dose MP during the study time period. Of these, 14 (28%) failed to respond to standard MP dose treatment; 10 out of the 14 were treated with high-dose MP. Mean patient age for the 10 children was 9.8 years (range 0.42-16.97 years); 8 were boys. Other demographic and transplant-related information is presented in Table 1 . All patients were planned to receive four MTX doses and Table 1 Demographic information for 10 patients with aGVHD resistant to low-dose corticosteroid therapy who received high-dose corticosteroid therapy The median time to develop aGVHD symptoms was 16.5 days (range: 10-32 days) post HSCT. At initiation of standard dose MP, four patients had grade II aGVHD, four had grade III aGVHD and two had grade IV aGVHD. Three patients had single organ involvement (skin: three patients) at presentation. Of the seven patients with multiple organ involvement, three had skin and liver aGVHD, two had skin and gut aGVHD and two patients had skin, gut and liver aGVHD. During aGVHD therapy, 10 biopsies were obtained in nine patients (three positive for liver aGVHD; two negative for gut aGVHD; two positive for gut aGVHD; two positive for lung GVHD; one positive for skin aGVHD). Nine patients had at least one biopsy that was positive for aGVHD.
Number of patients

MP therapy
Ten of the 14 children who failed to respond to initial standard MP dose treatment received high-dose MP as salvage therapy. These children had received MP 2 mg/kg/day as initial therapy of aGVHD at a mean of 1.3 days (range: 0-9 days) after diagnosis of aGVHD. When high-dose MP was started, 10 patients had skin, 7 gut, 5 liver and 1 lung GVHD. Only one patient with isolated skin aGVHD did not have visceral involvement at initiation of high-dose MP. Five of the 10 children had grade IV aGVHD, 4 had grade III and 1 patient had grade II aGVHD.
High-dose MP therapy was given at a dose of 30 mg/kg/day (nine patients) or 20 mg/kg/day (one patient) followed by a tapering dose. The median time to start high-dose MP therapy after initiation of standard dose MP therapy was 12 days. One patient had received a trial of daclizumab in the interim.
The mean duration of high-dose MP administration was 3.5 days (range: 3-5 days). The MP dose was then tapered at a rate determined by the treating team. The duration of corticosteroid administration was evaluable in nine patients. The mean time these patients continued to receive MP or prednisone in tapering doses was 95 days (range: 36-439 days). During this time, five patients were switched from IV to oral steroid therapy and three also received topical steroid treatment.
Of the 10 patients who received high-dose MP therapy, only one had a CR (10%), and did not need further therapy. At initiation of high-dose treatment this patient had grade III aGVHD (stage 2 liver, stage 3 skin). This patient responded within 2 days and a tapering MP schedule was started. Of the nine patients who failed to respond to high-dose MP, two had a PR initially but needed further therapy with daclizumab and mycophenolate mofetil because of worsening of aGVHD on tapering of high-dose MP therapy. All nine patients who failed to respond to both standard and high-dose MP therapy continued to receive calcineurin inhibitor therapy and went on to receive other salvage therapies.
Morbidity and mortality
All patients developed hypertension for which they received treatment. A total of six children developed hyperglycemia. Three patients received insulin by continuous infusion to maintain normal blood sugar concentration.
Four infectious complications were seen in the 10 children who received high-dose MP: 2 cases of fatal proven fungal infection and 2 cases of non-fatal adenoviral infections. Other complications attributed to MP administration by the clinical team were severe myopathy 1 and psychosis. 1 Five of the 10 patients who received high-dose MP therapy died (50%). Causes of death included two cases of proven fungal infection, one case of multi-organ failure and one case of respiratory distress syndrome. Another patient died of relapse of the primary diagnosis at 14 months post HSCT. On average, non-relapse-related mortality occurred 53 days after HSCT (range: 43-74 days).
Discussion
We describe the experience in our institution with the practice of giving high-dose MP (20 or 30 mg/kg/day) to patients with aGVHD who fail to respond to MP 2 mg/kg/ day. Only 1 of 10 such patients had a sustained response to this intervention.
In children not receiving MP for aGVHD prophylaxis, the standard treatment for aGVHD is IV MP 2 mg/kg/day. 13 The reported response rate to this standard regimen ranges in the literature from as high as 71% 14 to only 35%. 4 This leaves a large proportion of patients who require secondline therapy for aGVHD. However, there is no published, evidence-based algorithm to guide the treatment of corticosteroid-resistant aGVHD.
Corticosteroids have profound anti-inflammatory and immunosuppressive properties and high-dose corticosteroid therapy interferes with processes that are essential for the activation and maintenance of lymphocytes. 15 High-dose or pulse corticosteroid therapy is a well-known treatment for various rheumatologic and immunologic diseases. 16 Pulse therapy is also often used to treat flares of autoimmune diseases. 16 It is known that corticosteroids have different mechanisms of action depending on the dose administered. 16 A high-dose corticosteroid regimen will cause glucocorticoid receptor saturation and will result also in significant downregulation of receptor binding sites. 17 This regimen also induces apoptosis in the lymphocytes. 18 These facts explain the success of high-dose corticosteroid regimens in immune-mediated diseases. However, the underlying mechanisms for the activity of corticosteroids in aGVHD remain debatable and the question of whether giving corticosteroids in high doses will lead to improved outcomes remains unanswered though it remains a common practice.
Reports on the use of higher doses of corticosteroids as second-line therapy for aGVHD resistant to lower doses are sparse. The Italian Cooperative Transplant Group compared MP 2 mg/kg/day with 10 mg/kg/day as initial therapy of aGVHD in 95 patients. Results in the two dosing groups were similar with respect to response rate (68% vs 71%, respectively), as well as morbidity and mortality rates. However, in 26 patients who failed to response to 2 mg/kg/day by the fifth day of therapy and were switched to 10 mg/kg/day, a high treatment-related mortality rate was observed (46%). The authors concluded that MP 2 mg/kg/day is as effective as a higher dose in treating aGVHD, and patients who do not respond to standard dose MP (2 mg/kg/day) should receive therapy other than corticosteroids. 19 In a randomized trial, Knop et al. 20 treated adult patients with steroid-resistant aGVHD with MP 10 mg/kg plus OKT3 vs MP 10 mg/kg alone. Only 7 out of the 40 (18%) patients who received high-dose MP alone were alive without aGVHD on day 100 compared to 33% of patients who had received high-dose MP and OKT3.
Oblon et al. 21 reported on seven adult patients who developed aGVHD after unrelated donor HSCT. They were treated with an initial MP dose of 5 mg/kg/day for 4 days followed by dose escalation to 10 mg/kg/day for nonresponders. Five of seven patients responded to the initial dose whereas two patients who failed to respond to 5 mg/ kg/day responded to the dose escalation. However, a flare of aGVHD during the MP taper was seen in patients receiving both doses. The good initial response to MP in patients receiving unrelated donor HSCT was similar to previous observations made by the same group in a related donor population. 22 Van Lint et al.
14 used a higher dose of MP (5 mg/kg/day for 5 days) as a second-line therapy on failure to respond to 5 days of MP 2 mg/kg/day therapy. Patients were randomized to receive either MP 5 mg/kg/day alone or in combination with antithymocyte globulin. Response rate was assessed 1 month after initiation of second-line treatment. Of the 34 patients who received MP alone, 24% had CR; PR and stable aGVHD were observed in 24 and 38% of the patients, respectively. The authors concluded that higher doses of MP may increase response rates in patients resistant to standard doses.
In this study, nearly all our patients who failed to respond to standard dose MP therapy failed to respond to high-dose MP therapy. All non-responding patients required further immunosuppressive therapy to control aGVHD symptoms. The population of patients treated with high-dose MP therapy was at high-risk for treatment failure, as nine patients had grade III or IV aGVHD, and nine patients had visceral organ involvement. Three patients responded initially to high-dose MP therapy; however, two patients progressed during tapering and required additional therapy. As only one patient in our series had CR, we conclude that a second-line therapy other than high-dose MP therapy should be considered in patients with aGVHD who fail to respond to MP 2 mg/kg/day.
Like other investigators 19, 23 we did not observe a response when the MP dose was increased. Van Lint et al., however, did observe a response to higher corticosteroid doses. Reasons that our findings may differ from those of Van Lint et al. are twofold. First, some patients identified as responders to high-dose MP by Van Lint et al. may have responded to standard dose MP had standard dose therapy been continued. Second, all but one of our patients had severe aGVHD (grades III-IV), which is known to be associated with a decreased likelihood of a favorable response to any therapy 5 whereas Van Lint et al.
14 included patients with grade I aGVHD. Importantly, the use of high-dose corticosteroids is also associated with significant adverse effects and mortality. Hypertension, infection, hyperglycemia and myopathy are commonly associated with corticosteroid therapy for aGVHD. 22, 23 Substantial toxicity was found in adults with aGVHD treated with MP in doses of 5 mg/kg/day or more including viral and fungal infections. 21 In our cohort of patients, the use of high-dose MP therapy was associated with toxicity including four proven infectious episodes.
In conclusion, in HSCT patients with aGVHD unresponsive to MP 2 mg/kg/day, second-line therapy with high-dose corticosteroids (20 or 30 mg/kg/day) is not effective. Interventions other than corticosteroid dose escalation should be explored in patients with corticosteroid-resistant aGVHD.
